Cognition Therapeutics Inc

Phase‑2 results for Cognition Therapeutics’ Zervimesine show promise in slowing Dementia with Lewy Bodies, a breakthrough in neurodegenerative drug development.

Cognition Therapeutics, Inc. is a biopharmaceutical company focused on developing small molecule therapeutics to target toxic proteins contributing to cognitive decline in Alzheimer’s disease and other degenerative brain disorders.

Cognition Therapeutics Inc. is a biopharmaceutical company making progress in its mission to combat Alzheimer’s disease and other degenerative brain disorders through innovative research and development.

Cognition Therapeutics Inc. continues to advance its research on Alzheimer’s disease and other degenerative brain disorders through its innovative approach to developing small molecule therapeutics.

Cognition Therapeutics, a pioneering biopharmaceutical company, is working to combat Alzheimer’s disease and other degenerative brain conditions through innovative small molecule therapeutics.

Cognition Therapeutics, a Pittsburgh-based biopharmaceutical company, is working to develop small molecule therapeutics to target toxic proteins and halt or reverse the progression of Alzheimer’s disease and other degenerative brain disorders.